Business
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025
MINNEAPOLIS, May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene
About this update from Bio-techne Corp
[{"type":"text","content":"MINNEAPOLIS, May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13th – 17th at the New Orleans Ernest N. Morial Convention Center.\nBio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope™ protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak™ GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo™ System will also be featured, with this state-of-the-art instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run.\nLeading researchers along with Maithreyan Srinivasan, PhD, Chief Scientific Officer, Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will present the latest innovations with RNAscope technology at ACD's symposium on Wednesday, May 14th at 8:30 am in room 383-385. This session will highlight NextGen RNAscope™ Multiomics Solutions for Spatial Precision: AAV, small RNA, CAR-T, and Beyond. Our distinguished guest speakers include:\nAdrian Veres, MD, PhD, Cofounder & Chief Scientific Officer at Dyno Therapeutics will present on \"In Vivo Validation of AI-designed AAV Capsids for Targeted Gene Delivery to NHPs.\"William (Wes) Salomon, PhD, Senior Director, Delivery Biology, Tessera Therapeutics will speak on \"Visualizing RNA Gene Writer Activity in Mouse Liver for the Potential Therapeutic Correction of Monogenic Disease Mutations.\"Another talk, moderated by Edward Pavina (Bio-Techne) will be presented on Thursday, May 15th from 12:15 – 1:15 PM in Room 383: \"Protein Quantitation Applications to Advance Gene Therapy Development – From Discovery Through Analytical Development\" with guest Speakers Julyana Acevedo PhD, Analytical Development Scientist, Sangamo Therapeutics and Nicolas Tricaud PhD, Co-fo...